ZD1839 (Iressa ™): A New Targeted Therapy for Solid Tumors

ZD1839 (Iressa™): A New Targeted Therapy for Solid Tumors Guest Editors: David H. Johnson, Christian Manegold Oncologist 2002; 7(Suppl 4): 1-41 Target Audience: Physicians who wish to advance their current knowledge of cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional).

• Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy EXPIRED